Trevor Magee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Trevor Magee has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jay Modi
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
5 shared publications - Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
5 shared publications - Alicia Ito Ford
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
4 shared publications - Garrett Jones
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
4 shared publications - Kimberly Magana
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
4 shared publications - Kyle Fitzgerald
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
4 shared publications
Latest Publications
- Open Access
- 15 August 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 41, 101347
Assessing core outcome set uptake in randomized controlled trials for chronic kidney disease: Cross-sectional analysis
- 15 August 2024
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 41, 101347
Open AccessAssessing core outcome set uptake in randomized controlled trials for chronic kidney disease: Cross-sectional analysis
- 5 June 2024
- Published by Springer Nature in Quality of Life Research
- Vol. 33 (8) , 2275-2283
Assessing uptake of the core outcome set in anxiety disorder clinical trials: a cross-sectional analysis
- 5 June 2024
- Published by Springer Nature in Quality of Life Research
- Vol. 33 (8) , 2275-2283
Assessing uptake of the core outcome set in anxiety disorder clinical trials: a cross-sectional analysis
- 7 January 2024
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 207, 111085
Assessing the uptake of the type 1 diabetes core outcome set in randomized controlled trials: A Cross-Sectional study
- 7 January 2024
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 207, 111085
Assessing the uptake of the type 1 diabetes core outcome set in randomized controlled trials: A Cross-Sectional study
- 1 January 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 211 (1) , 48-54
Reporting of Harms in Randomized Controlled Trials Published in Urology Journals: An Updated Analysis
Harms are often overlooked, but important, outcomes of randomized controlled trial reporting. Our goal was to determine if harms reporting has improved in high-impact urology journals. Randomized controlled trials published in The Journal of Urology®, Urology, European Urology, and BJU International in 2012 and 2020 were analyzed. Each randomized controlled trial was evaluated by 2 authors in a masked-duplicate fashion to evaluate for adherence to harms reporting guidelines recommended by the Consolidated Standards of Reporting Trials (CONSORT) group. One hundred and thirty-two published studies met inclusion criteria. Between 2012 and 2020, there was a statistically significant increase in the median number of harms criteria reported between 2012 and 2020 (5.3 vs 7.2; P = .01). Methods criteria demonstrating the greatest improvements included item #3 "which harms were assessed," item #4a "when harm information was collected," and item #4b "methods to attribute harm to intervention." Results sections with the most improvement in reporting include item #6 "reasons for patient withdrawal," item #8a "effect size for harms," and item #8b "stratified serious + minor harms." Reporting of adverse events in randomized trials published in several top urology journals has demonstrated marked improvement. Studies published in 2020 reported approximately 70% of CONSORT-Harms criteria-an increase of nearly 40% since 2004. While these improvements mark significant change, deficits remain present and should be addressed to provide clinicians with the most complete perspective possible.
- 1 January 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 211 (1) , 48-54
Reporting of Harms in Randomized Controlled Trials Published in Urology Journals: An Updated Analysis
Harms are often overlooked, but important, outcomes of randomized controlled trial reporting. Our goal was to determine if harms reporting has improved in high-impact urology journals. Randomized controlled trials published in The Journal of Urology®, Urology, European Urology, and BJU International in 2012 and 2020 were analyzed. Each randomized controlled trial was evaluated by 2 authors in a masked-duplicate fashion to evaluate for adherence to harms reporting guidelines recommended by the Consolidated Standards of Reporting Trials (CONSORT) group. One hundred and thirty-two published studies met inclusion criteria. Between 2012 and 2020, there was a statistically significant increase in the median number of harms criteria reported between 2012 and 2020 (5.3 vs 7.2; P = .01). Methods criteria demonstrating the greatest improvements included item #3 "which harms were assessed," item #4a "when harm information was collected," and item #4b "methods to attribute harm to intervention." Results sections with the most improvement in reporting include item #6 "reasons for patient withdrawal," item #8a "effect size for harms," and item #8b "stratified serious + minor harms." Reporting of adverse events in randomized trials published in several top urology journals has demonstrated marked improvement. Studies published in 2020 reported approximately 70% of CONSORT-Harms criteria-an increase of nearly 40% since 2004. While these improvements mark significant change, deficits remain present and should be addressed to provide clinicians with the most complete perspective possible.
- 27 September 2023
- Published by Elsevier in Ageing Research Reviews
- Vol. 91, 102081
Assessing uptake of the core outcome set in randomized controlled trials for Parkinson’s disease: A systematic review
- 27 September 2023
- Published by Elsevier in Ageing Research Reviews
- Vol. 91, 102081
Assessing uptake of the core outcome set in randomized controlled trials for Parkinson’s disease: A systematic review
- 3 June 2023
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 152, 209082
Inequities in the treatment of opioid use disorder: A scoping review
- 3 June 2023
- Published by Elsevier in Journal of Substance Use and Addiction Treatment
- Vol. 152, 209082
Inequities in the treatment of opioid use disorder: A scoping review
- 27 September 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 129 (5) , 767-775
An analysis of harms reporting in systematic reviews regarding ketorolac for management of perioperative pain
- 27 September 2022
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 129 (5) , 767-775
An analysis of harms reporting in systematic reviews regarding ketorolac for management of perioperative pain